reference/27805306

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27805306

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article
endingPage	1566
issn	1349-7006 1347-9032
issueIdentifier	4
pageRange	1556-1566
publicationName	Cancer Science
startingPage	1556
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4b711ffdbe8af5c8f3f9c53da46d83fa http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_2c917b9de44de627ddb0a3eaab982fd0
bibliographicCitation	Seto T, Ohashi K, Sugawara S, Nishio M, Takeda M, Aoe K, Moizumi S, Nomura S, Tajima T, Hida T. Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study. Cancer Science. 2021 Feb 24;112(4):1556–66. doi: 10.1111/cas.14826.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f60b43638ea7ca63f5491e52c0cf054d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1dd62728be56ab79ebe52f6ce7751bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4969-4165 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3537-0020 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87b21e691ff66b4e76a6f07f4ca84028 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1990861158d97a21680d9e8bf40a296c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_36a28bb7268110e542b00a8541143340 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5853-1435 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00c9d2cbca51996e140435f3bb6da55c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f4a47beb7f86346901f203db33cdd8e1
date	2021-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1111/cas.14826 https://pubmed.ncbi.nlm.nih.gov/33506571 https://pubmed.ncbi.nlm.nih.gov/PMC8019204
isPartOf	https://portal.issn.org/resource/ISSN/1347-9032 https://portal.issn.org/resource/ISSN/1349-7006 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/30320
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
discusses	http://id.nlm.nih.gov/mesh/M0468309 http://id.nlm.nih.gov/mesh/M000626242 http://id.nlm.nih.gov/mesh/M0011048 http://id.nlm.nih.gov/mesh/M0021908 http://id.nlm.nih.gov/mesh/M0002327 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0029482
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D007093Q000627 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D005091Q000235 http://id.nlm.nih.gov/mesh/D014227Q000627 http://id.nlm.nih.gov/mesh/D019859Q000235 http://id.nlm.nih.gov/mesh/D002289Q000235 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D008175Q000235
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D007564 http://id.nlm.nih.gov/mesh/D009154 http://id.nlm.nih.gov/mesh/D001549 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25145656 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID588 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7548

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4233

Total number of triples: 62.